Cited 0 times in
PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김상겸 | - |
dc.contributor.author | 김승현 | - |
dc.contributor.author | 김지형 | - |
dc.contributor.author | 김효송 | - |
dc.contributor.author | 백우열 | - |
dc.contributor.author | 우하영 | - |
dc.contributor.author | 이영한 | - |
dc.contributor.author | 전민경 | - |
dc.contributor.author | 한정우 | - |
dc.date.accessioned | 2021-04-29T17:36:44Z | - |
dc.date.available | 2021-04-29T17:36:44Z | - |
dc.date.issued | 2021-03 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/182434 | - |
dc.description.abstract | Background: Pazopanib, a multitargeted tyrosine kinase inhibitor, is recommended as the standard treatment for refractory soft tissue sarcoma (STS). However, there are comparatively few molecular determinants for predicting pazopanib efficacy. Based on correlative studies regarding the predictive impact of PD-L1, we investigated the clinical relevance of PD-L1 expression and evaluated its value for predicting pazopanib efficacy. Methods: Tumour tissues from patients with advanced STS who went on to receive pazopanib were assessed for PD-L1 expression. Immunohistochemistry was performed using an anti-PD-L1 antibody, and the PD-L1 tumour proportion score (TPS) was calculated as the percentage of at least 100 viable cells with positive expression, defined as TPS ≥ 1%. Results: Among the 67 patients, 8 (11.9%) achieved partial response and a median progression-free survival (PFS) of 4.8 months (95% CI 3.8-5.7). PD-L1 expression in tumour cells was detected in 13 (19.4%) cases and the TPS scores ranged from 1 to 100%, as follows: 0 (n = 54, 80.6%), 1-9% (n = 3, 4.5%), 10-49% (n = 9, 13.4%), and ≥ 50% (n = 1, 1.5%). PD-L1 positive tumours exhibited a poorer response to pazopanib treatment than the PD-L1 negative tumours (0% vs 14.8%, P = 0.07). PD-L1-positive tumours had significantly shorter PFS than the PD-L1-negative tumours (median PFS 2.8 vs 5.1 months, P = 0.003), and PD-L1 positivity was an independent predictor of poor response to pazopanib treatment (HR 2.77, 95% CI; 1.45-5.56, P = 0.006). Conclusion: We identified that PD-L1 expression can help predict the clinical outcome of patients with advanced STS treated with pazopanib. Based on our study, stratification should be actively considered in order to identify patients who will benefit from pazopanib or further therapeutic strategies for future clinical trials. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | BioMed Central | - |
dc.relation.isPartOf | BMC CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pathology (병리학교실) | - |
dc.contributor.googleauthor | Sang Kyum Kim | - |
dc.contributor.googleauthor | Jee Hung Kim | - |
dc.contributor.googleauthor | Seung Hyun Kim | - |
dc.contributor.googleauthor | Young Han Lee | - |
dc.contributor.googleauthor | Jung Woo Han | - |
dc.contributor.googleauthor | Wooyeol Baek | - |
dc.contributor.googleauthor | Ha Young Woo | - |
dc.contributor.googleauthor | Min Kyung Jeon | - |
dc.contributor.googleauthor | Hyo Song Kim | - |
dc.identifier.doi | 10.1186/s12885-021-08069-z | - |
dc.contributor.localId | A00520 | - |
dc.contributor.localId | A00662 | - |
dc.contributor.localId | A00999 | - |
dc.contributor.localId | A01202 | - |
dc.contributor.localId | A04949 | - |
dc.contributor.localId | A04854 | - |
dc.contributor.localId | A02967 | - |
dc.contributor.localId | A05978 | - |
dc.contributor.localId | A04325 | - |
dc.relation.journalcode | J00351 | - |
dc.identifier.eissn | 1471-2407 | - |
dc.identifier.pmid | 33789622 | - |
dc.subject.keyword | Biomarker | - |
dc.subject.keyword | PD-L1 | - |
dc.subject.keyword | Pazopanib | - |
dc.subject.keyword | Soft tissue sarcoma | - |
dc.contributor.alternativeName | Kim, Sang Kyum | - |
dc.contributor.affiliatedAuthor | 김상겸 | - |
dc.contributor.affiliatedAuthor | 김승현 | - |
dc.contributor.affiliatedAuthor | 김지형 | - |
dc.contributor.affiliatedAuthor | 김효송 | - |
dc.contributor.affiliatedAuthor | 백우열 | - |
dc.contributor.affiliatedAuthor | 우하영 | - |
dc.contributor.affiliatedAuthor | 이영한 | - |
dc.contributor.affiliatedAuthor | 전민경 | - |
dc.contributor.affiliatedAuthor | 한정우 | - |
dc.citation.volume | 21 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 336 | - |
dc.identifier.bibliographicCitation | BMC CANCER, Vol.21(1) : 336, 2021-03 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.